Skip to main content
Toggle navigation
Login
Home
Favorite
Like
Post
Print
Daniel Weibel
Vaccine monitoring collaboration for Europe (VAC4EU), Brussels, Belgium, Netherlands
Poster(s):
(A-339) 2024 interim results from the VAC4EU post-authorisation safety study (PASS) for the Pfizer-BioNTech COVID-19 vaccine (Comirnaty®) in Europe
Sunday, August 24, 2025
12:00 PM - 1:30 PM
ET
(A-352) Barriers and Strategies to Improve Vaccine Adverse Events Reporting: Views from Health Workers and Managers in Northern Ghana
Sunday, August 24, 2025
12:00 PM - 1:30 PM
ET
(SLC-055) Clinical course and outcomes of myocarditis/pericarditis cases following mRNA-1273 vaccination compared to cases not following COVID-19 vaccination: interim analysis of a VAC4EU cohort study
Tuesday, August 26, 2025
12:15 PM - 1:15 PM
ET
(SLC-054) Risk factors for myocarditis/pericarditis following mRNA-1273 vaccination: interim analysis of a VAC4EU case-cohort study
Tuesday, August 26, 2025
12:15 PM - 1:15 PM
ET
(SLC-053) Risk of Venous Thrombosis With Thrombocytopenia Syndrome After Vaccination With AZD1222: A European VAC4EU Post-Authorisation Safety Study
Tuesday, August 26, 2025
12:15 PM - 1:15 PM
ET